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In this article, we described the development in the field of allergy as described by
Clinical and Experimental Allergy in 2017. Experimental models of allergic disease,
basic mechanisms, clinical mechanisms, allergens, asthma and rhinitis and clinical
allergy are all covered.
1 | ASTHMA AND RHINITIS
1.1 | Underlying mechanisms of asthma
Although novel technologies that allow unbiased detection of
biomarkers for diseases are being used increasingly their clinical
application remains uncertain.1 Omics approaches are high‐through-
put technologies that provide a cross‐sectional analysis of biological
systems including genomics (measure of DNA variation), transcrip-
tomics (assessment of RNA expression), epigenomics (DNA alter-
ations that influence RNA expression), proteomics (protein
expression) and most recently metabolomics (metabolite levels).
These analyses help to generate hypotheses about disease mecha-
nisms. In the context of asthma, however, they have also been used
to identify biomarkers that identify specific disease phenotypes
especially if current diagnostic techniques are not very helpful. One
such phenotype includes aspirin‐induced respiratory disease which
has featured in one Clinical and Experimental Allergy paper. Ban and
colleagues have used metabolomics profiling in both serum and urine
to assess differences between patients who have aspirin‐tolerant
asthma compared to those with aspirin‐exacerbated respiratory dis-
ease.2 They found that serum levels of leukotrienes (LTE4) and the
ratio of LTE4/prostaglandin (PGF2a) before and after an aspirin bron-
choprovocation test were significantly higher in patients with
aspirin‐exacerbated respiratory disease.
An advantage of metabolic profiling is the ability to give signals
in non‐invasive samples, such as urine and breathe. Metabolic pro-
files are being increasingly assessed in exhaled breath to find bio-
marker signatures that may identify clinical phenotypes and predict
of loss of asthma control. Exhaled breath volatile organic compounds
(VOCs) were measured in patients with partly controlled asthma as
part of a steroid withdrawal study.3 Two techniques were used,
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eNose and gas chromatography/mass spectrometry (GC/MS). Unbi-
ased analyses were applied to assess ability to predict loss of asthma
control. Breath profiles analysed by eNose predicted loss of control
in 95% of cases while GC/MS was accurate in prediction in between
68% and 77% of cases. Prediction of exacerbations and loss of con-
trol are a key component of asthma management, and these data
suggest exhaled breath compounds should be pursued in future
interventional studies to validate utility in a clinical setting.
The utility of an unbiased pathway‐based association study was
applied from a previous genomewide association study (GWAS) of
asthma to identify novel asthma susceptibility genes by Barreto‐Luis
et al.4 Significant biological pathways using a gene‐set enrichment
analysis from the GWAS were identified, and all tested SNPs on sig-
nificant gene pathways were identified and those with a dispropor-
tionate number of nominal significant associations were prioritized.
Analyses revealed two biological processes that were significantly
enriched including a known asthma susceptibility locus (encoding
SMAD family member 3), but also a novel susceptibility locus near
Wnt signalling genes, which may be associated with fibrosis and air-
way remodelling, thus highlighting a potential novel mechanistic ave-
nue and pathway to be interrogated in asthma.
One of the key components of asthma pathophysiology, in addi-
tion to airway inflammation,5,6 is airway structural change, or remod-
elling. Increasingly mechanistic studies show structural airway cells
are immunologically active and contribute to disease manifestation. A
group of manuscripts in Clinical and Experimental Allergy over the
last year have shown the importance of investigating the interactions
between airway structural and immune cells to find novel therapeutic
avenues. The bronchial epithelium is undoubtedly central to asthma
pathogenesis with multiple functions. Winnica and colleagues have
demonstrated reduced nitric oxide (NO) formation and increased
oxidative and nitrosative stress in primary bronchial epithelial cells
from asthmatics.7 This was restored towards normal NO formation
following L‐citrulline supplementation. This shows mechanistic differ-
ences in epithelial cell function and also proposes the utility of L‐
citrulline as a potential therapeutic to restore function. An important
phenotypic change in the bronchial epithelium in asthma includes
goblet cell metaplasia and associated functional increased mucus pro-
duction. The impact of corticosteroids alone or in combination with
long‐acting beta agonists on goblet cell metaplasia and the mecha-
nisms involved was investigated by Lachowicz‐Scroggins and col-
leagues.8 Corticosteroids alone inhibited IL‐13‐induced goblet cell
metaplasia, and the addition of long‐acting beta agonists had an addi-
tive effect of reduced goblet cell metaplasia and mucus secretion.
Given that mucous production is an important feature of obstructive
airway disease, this may be an important therapeutic mechanism.
Another structural cell that is significantly altered in asthma is
airway smooth muscle. The role of the inflammatory cytokine calpain
(a family of calcium‐dependent endopeptidases), which are important
role in extra‐cellular matrix remodelling, was investigated in airway
smooth muscle remodelling by Rao et al.9 Calpain was shown to
mediate cytokine‐induced collagen‐I synthesis and proliferation of
airway smooth muscle cells via the mTORC2/Akt signalling pathway
in a murine model and thus shown to play a role in regulating airway
smooth muscle remodelling in asthma.
The range of mechanistic studies undertaken and published in
the journal is highlighted by the data from the manuscript by
Low et al.10 The difficulty of disentangling vocal cord dysfunction
from true wheeze in patients with asthma remains a significant
clinical challenge. However, it is likely that in many patients, they
are not completely distinct but overlap. The presence of paradox-
ical vocal cord movement (PVCM) and whether it is associated
with airflow limitation or other disease characteristics of asthma
were investigated. PVCM was quantified using dynamic 320‐slice
computerized tomography of the larynx. Approximately a quarter
of all patients with asthma had evidence of PVCM, and this was
more frequently associated with airflow limitation. This unex-
pected relationship highlights the relatively high prevalence of
PVCM in asthma and the need to investigate mechanistic interac-
tions between extrathoracic airway obstruction and lower airway
obstruction in asthma.
Finally, Davies and colleagues have published some interesting
data showing a clear inverse association between hospitalization
rates for children with asthma and total hours of sunshine in Eng-
land.11 Is this related to vitamin D or socioeconomic factors?
1.2 | Asthma clinical phenotypes
We are increasingly understanding asthma phenotypes as reviewed
by Just and colleagues.12 An asthma phenotype, in which both diag-
nosis and management are challenging, is fungal sensitization.
Immunological and inflammatory diagnostic biomarkers were related
to clinical features including lung function and CT scan structural
pathology in adults with fungal allergy and asthma by Woolnough et
al.13 Unbiased cluster analyses revealed specific IgE sensitization to
fungi, specifically thermotolerant fungi including Aspergillus fumigatus
was associated with fixed airflow limitation; no relationship was seen
with total serum IgE. This highlights the risk of lung damage from
fungal allergy in all asthmatic patients with positive‐specific IgE to fil-
amentous fungi, not just those who meet the criteria for allergic
bronchopulmonary aspergillosis (ABPA).
Disentangling asthma and chronic obstructive pulmonary disease
(COPD) have increased in complexity with development of greater
insights into the immunology. Cluster analysis in the hunt for more
precise phenotypes has become more sophisticated in terms of fac-
tors used as discriminators for both asthma and COPD and for over-
laps between them. In a study, Hiriai and colleagues looked at the
usual factors plus mRNA for a variety of transcription factors; they
found four clusters, COPD, asthma‐COPD overlap, late‐onset non‐
atopic asthma and early‐onset atopic asthma.14 Perhaps reassuringly
the asthma‐COPD overlap cluster showed an overlapping of asthma
and COPD features with atopy, eosinophilia and raised IgE but with
worse lung function and a history of smoking. Presumably the “acid”
test of this sort of increasingly sophisticated phenotype development
will be treatments that target the appropriate immunological fea-
tures.
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1.3 | Asthma clinical management
The importance of stepping down inhaled corticosteroid (ICS) treat-
ment in asthma has long been recognized. The criteria and factors
that might inform this process are less clear than have those for
stepping up ICS treatment. Saito and colleagues have looked at some
of these factors using a factor analysis approach.15 Upper airway
complications, psychiatric morbidity and poor adherence to ICS were
examined for their effects on a step down programme. Perhaps
unsurprisingly, poor adherence to ICS was the most strongly predic-
tive of failure to step down followed by upper airway complications.
Interestingly, psychiatric factors did not lead to significant step down
failure on its own but it did increase problems in conjunction with
the other two factors. This study suggests that factors other than
just the state of a patient's asthma should be considered and reme-
died before a ICS reduction is considered.
Bjerregaard and colleagues have studied stable adult asthmatics
from a specialist outpatient clinic.16 Participants with elevated spu-
tum eosinophils or elevated FeNO were found to be at greater risk
of future viral‐induced asthma exacerbations. It is not clear if this is
an interaction between virus and type 2 inflammatory markers or
simply that any exacerbation will tend to be more severe in those
with elevated markers. The authors argue that understanding these
interactions will be important in personalizing future antibody treat-
ments.
There has long been an interest in the question of corticosteroid
resistance amongst patients with severe asthma. Sousa and col-
leagues have explored this amongst a group of moderate and severe
asthmatics.17 Following a two‐week course of oral prednisolone,
both groups experienced a similar degree of suppression of blood
and airway eosinophilia and serum cytokines. Even in patients on
high doses of inhaled steroids, many showed a suppressive eosino-
phil response. As would be expected oral corticosteroids increased
airway and blood neutrophils but interestingly airway neutrophilia
was greater amongst the more severe asthmatics suggesting that
neutrophils in severe asthma are related to corticosteroids therapy.
Electronic medical records from 1.4‐m adult patients in primary
care have been analysed to compare co‐morbidities in patients with
active asthma defined by read code and recent prescribed therapy
and those without.18 Almost all of the 39 co‐morbidities were signifi-
cantly more common amongst those with active asthma. Many are
not surprising, COPD, bronchiectasis, eczema, other are less easily
explained, chronic pain, hypertension, irritable bowel syndrome.
Depression and anxiety were both more common as has been shown
in many studies. Some of the co‐morbidity may be related to more
frequent primary care contact but, as the authors point out, it has
implications for studies of new asthma treatments where many
comorbidities are excluded and for patient management where some
of these, especially depression and anxiety, may need to be man-
aged.
In this clinical study, Jabbal and colleagues explore one
possible mechanism by which tiotropium added to ICS/LABA com-
binations might reduce asthma exacerbations.19 They explore the
idea that LAMA's might reduce LABA‐induced beta2 receptor
down regulation by receptor cross‐talk thereby reducing airway
hyperresponsiveness. This turned out not to be the case, at least
for mannitol airway hyper‐responsiveness amongst mild/moderate
asthmatics, suggesting that other mechanisms such as remodelling
or anti‐inflammatory effect of tiotropium may be responsible.
However, tiotropium is currently considered as an option for steps
4 and 5 of the Global Initiative for Asthma in poorly controlled
asthma.
Asthma and psychological disorders seem to be closely associ-
ated. Chang and colleagues published data demonstrating an inde-
pendent association among suicidal ideation, asthma and bronchial
hyperresponsiveness in adolescents.20
It is getting increasingly difficult to know which biological to use
in severe asthma. Cabon and colleagues have undertaken a system-
atic review and indirect meta‐analysis of anti‐interleukin‐5 (IL‐5) ther-
apies for severe asthma.21 They found that all the IL‐5 blockades
have similar efficacies and similar adverse effects.
1.4 | Rhinitis
Many cross‐sectional studies have found associations between
reported damp mouldy environments and a variety of self‐reported
respiratory symptoms. In a study taken from the Swedish Galen
study amongst 26 000 adults, these self‐reported associations are
again confirmed.22 In addition, there were similar associations
between dampness and chronic rhinosinusitis. Also, they reported
some evidence for a dose‐response relationship in terms of the num-
ber of positive dampness measures. The key question in these stud-
ies is the potential mechanism for these associations, assuming of
course that they are indeed causal.
Many patients with chronic upper airway disease complain that
alcohol worsens their symptoms. Derycke and colleagues surveyed
1281 subjects and then looked at inflammatory markers in a sub-
set.23 Alcohol‐related problems were commonest with NSAID exac-
erbated respiratory disease then chronic rhinosinusitis with nasal
polyps and less so with chronic rhinosinusitis patients without nasal
polyps and allergic rhinitis. This was associated with significantly
higher nasal levels of the eosinophilic biomarker ECP.
Pfaar and colleagues described the dose‐response characteristics
of a new Timothy grass pollen allergoid immunotherapy product in
comparison with a 6‐grass pollen allergoid.24 Both had similar effica-
cies. There has been discussion about the appropriate end‐point for
trials. Vicaut and colleagues use data from five previous trials to
compare end‐points.25 In each study, the Combined Score or
Adjusted Symptom Score gave similar results.
Some novel interventions for allergic rhinitis have also been
described in Clinical and Experimental Allergy. Ellis and colleagues
described a beneficial effect of an intranasal TLR7 agonist
(GSK2245035).26 Meanwhile, Berrings and colleagues describe how
probiotics‐impregnated bedding covers reduced house dust mite
allergic rhinitis symptoms although allergens levels were not
altered.27
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2 | CLINICAL ALLERGY
2.1 | Anaphylaxis
The Royal College of Anaesthetists 6th National Audit Project exam-
ined perioperative anaphylaxis over one year in the UK.28 A total of
266 cases met the inclusion criteria, three‐quarters with an identified
trigger. Egner and colleagues call for a harmonization of approach to
testing, access to services and MHRA reporting. They also emphasized
the need to involve expert anaesthetists in managing these cases.
Motomura and colleagues have examined the effect of aspirin on
challenge tests for food‐dependent exercise induced anaphylaxis.29
Twenty‐six children had positive challenges. In half the combination
of food and exercise induced allergic symptoms. Aspirin induced a
positive reaction in 14 patients who had no or mild symptoms just
with food and exercise. So we now need to think about combinations
of three factors when understanding the precipitants of anaphylaxis.
Low‐osmolar non‐ionic radiocontrast media are in common use
in clinical practice. Kim and colleagues have looked at the rate of
adverse reactions to these in one hospital.30 Iopromide was associ-
ated with most immediate reactions (1.03%) followed by iopamidol
(0.67%), iohexol (0.64%) and iobitridol (0.34%).
Mastocytosis is associated with a high prevalence of anaphylaxis.
Zanoni and colleagues have looked at rates of vaccine reactions in
their mastocytosis clinic.31They saw very few reactions and only rec-
ommend extending the normal 15‐minute observation period to
30 minutes along with training for parents in how to recognize and
manage allergic reactions.
Finally, Stretz and colleagues looked at whether temporary
omalizumab co‐treatment with high maintenance venom dose can pre-
vent recurrent systemic allergic reactions with venom immunother-
apy.32 Their retrospective, observational case series with 10 patients
on combination therapy and five just on immunotherapy suggested
that a short course of omalizumab is very helpful in this group.
2.2 | Food allergy
We now have a much better understanding about how childhood
food allergy develops. The review by Foong and Brough nicely sum-
marizes this.33 We also have an improving understanding of the
allergens that induce allergy reactions to foods as exemplified by
Sharp and colleagues review on fish allergens.34 It also seems that
there are specific patterns or phenotypes of food allergy.35 Finally,
Stensgaard and colleague have demonstrated the major impact that
food allergy has on the whole family.36
Diagnosing food allergy remains a challenge with food provoca-
tion challenges frequently being required. van der Valk and col-
leagues have described, in a prospective study, how specific IgE to
components Ana o 1, 2 and 3 can be used to diagnosis children with
suspected cashew nut allergy.37 Another approach, which is become
more established, is the basophil activation test which Santos and
Shreffler reviewed.38 There are some novel approaches, and Lindvik
and colleague published data from 81 children demonstrating that
conjunctival provocation testing has a sensitivity and the specificity
of 0.96 and 0.83, respectively, for peanut allergy.39 None had a sev-
ere adverse reaction with this approach where as a quarter had an
anaphylactic reaction with the food challenge.
We are still working on effective therapies for food allergies. A
popular approach is to initiate patients with cow's milk or egg allergy
on baked milk or baked egg, respectively.40 Unfortunately, there
seems to be limit evidence to suggest that this approach speeds up
outgrowth although it may simplify meals times for families.41 A
potential treatment strategy is omalizumab, and Vetander and col-
leagues publish data to suggest that an individualized dosing can
prevent reactions in patients with food allergy.42 Specific
immunotherapy is another option although serious adverse events
are not infrequent.43 An alternative route is to utilize an allergen
that has been processed to reduce its allergenicity without reducing
its immunogenicity. Tao has described how boiled peanuts are asso-
ciated with less reactions than expected in an observational cases
series of children undergoing peanut oral allergen immunotherapy
(OIT).44 Promising but needs to be tested against conventional OIT
protocols. Finally, the psychological issues associated with food
allergy need to be addressed. Boyle and colleagues have published a
randomized controlled trial looking at a brief psychological interven-
tion for food allergy.45 They found that anxiety could be reduced in
mother with moderate/high anxiety at enrolment.
2.3 | Eczema
Perhaps the most convincing evidence for the preventative impact
of probiotics is for eczema. Peldan and colleagues have followed
their randomized control trial participants to 10 years of age. Perina-
tal probiotics were still associated with reduced eczema at
10 years.46 However, they were also associated with increased aller-
gic rhinoconjunctivitis as defined by the ISAC questions (130/337
[38.6%] vs 84/325 [25.8%]). While they suggest that it is likely to be
a false positive, long‐term follow‐up of other studies is obviously
required.
Also, Wang and colleagues have looked at the proteomic signa-
ture associated with eczema.47 They found unique proteomic signa-
tures in the serum which appear to potential distinguish different
inflammatory skin diseases. The authors suggest that this approach
might provide an insight into disease pathogenesis, diagnosis and
novel therapies.
3 | EPIDEMIOLOGY
3.1 | Early risk factor for atopic disease
The interest in early risk factors for subsequent asthma, rhinitis and
eczema with a special focus towards the hygiene hypothesis and
microbiota has been displayed in several publications in 2017. In a
Finnish study, significant differences were found in allergy preva-
lence between young people from Finnish and Russian Karelia.48
Skin microbiota, as well as bacterial and fungal communities in nasal
ROBERTS ET AL. | 1609
mucosa, was also contrastingly different between the populations,
and diversity of Actinobacteria was clearly associated with reduced
allergy in Russia. Early exposure to dogs has been reported to
decreases the risk of asthma,49,50 and Wegienka et al have now pro-
posed that there are subgroup differences (race, gender and delivery
mode) in the association.51 Laboratory animals do not offer a similar
protection towards asthma and allergic disease. Simoneti and col-
leagues have reported in Clinical and Experimental Allergy that aller-
gic sensitization to laboratory animals is more associated with
asthma, rhinitis and skin symptoms than sensitization to common
allergens.52 Exposure to antibiotics in fetal life does not seem to
increase the risk of asthma after taking family confounding such as
genes and shared environmental factors into account53 or using
paternal exposure as negative control.54 Timm and colleagues though
report an association between prenatal exposure to antibiotics and
increased risk of atopic dermatitis (AD) in the first 18 months of life
among children born to atopic mothers.55 Travelling is another risk
factor that may be associated with microbiota and also with socioe-
conomic status. Results from GINIplus and LISAplus show that early
life travelling does not increase the risk of atopic outcomes until
15 years of age.56 Nevertheless, there is a need to carefully interpret
potential causal effects and to take genetic and environmental con-
founding as well as residual confounding into account. We look for-
ward to future studies using family design and other innovative
methods.57,58
3.2 | Nutritional influences
Infant feeding patterns59 as well as dietary antioxidant60,61 and sub-
sequent allergic disease have also been in focus in 2017 Clinical and
Experimental Allergy, along with risks of asthma in overweight chil-
dren.62 Two interesting articles have focused on maternal distress or
psychiatric symptoms before and during pregnancy, and later risk of
childhood eczema or atopic disease.63,64 In the Southampton
Women's Survey, an association was found between maternal stress
before pregnancy and offspring risk of eczema at 12 months. There
was also somewhat increased risk of offspring eczema among moth-
ers with symptoms postnatally but not after taking account of pre‐
conception stress.65 These findings confirm the importance to
address critical exposure periods or cumulative exposure to maternal
distress over pregnancy66 and also point to potentially modifiable
influences. The other study, from the Generation R, found that
maternal psychiatric symptoms during pregnancy were associated
with increased risks of childhood inhalant allergy and eczema, inde-
pendent of symptoms after delivery.64 They also adjusted their find-
ing for paternal psychiatric symptoms which highlights the
importance of using fathers as negative control.66
3.3 | Other epidemiological highlights
Finally, Clinical and Experimental Allergy has also included reports on
sensitization patterns for rhinitis and asthma multimorbidity from the
EGEA study,67 an association between DNA methylation of Th2
lineage determinants of genes at birth and later allergic outcomes in
the EpiGene consortium68 and expression of the filaggrin gene in
cord blood as predictor of eczema risk in infancy from the Isle of
Wight study.69
4 | EXPERIMENTAL MODELS OF ALLERGIC
DISEASE
4.1 | Mechanisms of allergic disease
4.1.1 | Immune mechanisms of allergic airway
disease
Allergen exposure of the pulmonary epithelium results in epithelial
cell‐derived production of cytokines such as TSLP, IL‐25 and IL‐33,
which are thought to launch the pro‐allergic type 2 cytokine
response through activation of innate lymphoid type 2 cells (ILC2)
and antigen‐specific CD4+ Th2 T cell response.70,71 The ILC2‐ and
CD4+ Th2 cell‐derived type 2 cytokines IL‐4, IL‐5, IL‐9 and IL‐13
promote IgE production and engagement of IgE‐FcεRI‐basophils and
MCs; tissue eosinophilia and MC hyperplasia; mucus production by
goblet cells and AHR, which are hallmark clinical manifestations of
allergic asthma.72
The antigen‐specific CD4+ Th2 T cell response is thought to be
mediated by DC presentation of pollen allergens to naïve CD4+ T
cells in the draining lymph nodes.70, 73 Critical steps for the DC‐
CD4+ type 2 cell polarization is the interaction of co‐stimulatory
molecules (CD28 and CD80/CD86; OX40L and OX40) between anti-
gen‐presenting cells (APCs) and T cells.74 A recent study by Moe
and colleagues demonstrated that the dust mite allergen Der-
matophagoides farina 8 (Der f8), a glutathione S‐transferase, induces
the expression of T cell immunoglobulin mucin domain 4 (TIM4) on
DC cells and provided evidence to support a role for TIM4 in the
expansion of CD4+ Th2 cells in the mouse allergic lung.75 Interest-
ingly, the authors show that direct stimulation of DCs with Derf8
induced TIM4 expression and that the induction of TIM4 on DC cells
was specific to Der f8 as stimulation of DCs with a Derf8‐deficient
dust mite extract (DME) did not stimulate TIM4 expression in
BMDCs. Employing an in vivo model, the authors show that expo-
sure of mice to Derf8 or DME and not Der f8‐deficient DME led to
the induction of allergic airway disease (AAD) in mice including
expansion of CD4+ cells, increased systemic Th2 cytokines, Derf8‐
specific IgE and pulmonary inflammation (eosinophils, neutrophils
and macrophages). Notably, the pulmonary allergic response was
inhibited by anti‐TIM4 mAb treatment suggesting that Derf8‐driven
allergic inflammatory phenotype was dependent on TIM4 activity.
Intriguingly, treatment of DME‐allergic mice with Derf8‐deficient
DME‐specific immunotherapy (SIT) reduced the pulmonary allergic
response and that this was associated with the development of anti-
gen‐specific CD4+ CD25+ FoxP3+ T regulatory (Treg) cells in the
lung. In support of an important role for TIM4 in the development
of CD4+ Th2 cell differentiation, previous studies by Lee et al have
demonstrated using a DC: CD4 T cell co‐culture system that
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blockade of TIM4 on DC's significantly inhibits Th2 cell differentia-
tion and facilitated the induction of CD4+ T reg cell expansion.76
The molecular action of how glutathione S transferases (GST) pro-
voke TIM4 expression on DC cells is not yet clear. The authors pro-
vided data showing that Der f8 induced the TIM4 gene transcription
through direct chromatin remodelling of the TIM4 gene locus.75
Another molecule recently linked with the exacerbation of the
allergic pulmonary inflammation and the asthma phenotype is the
Duffy antigen receptor for chemokines (DARC).77 DARC is mem-
brane‐bound atypical promiscuous chemokine receptor that binds
immunomodulatory ligands including CXC and CC chemokines and
cytokines.78 DARC is thought to act as chemokine Rheostat as it
lacks the characteristic Asp‐Arg‐Tyr (DRY) motif within the second
cytoplasmic loop characteristic of G‐protein coupled receptors and
therefore lacks classical GPCR signalling.79,80 Clinical studies have
reported an association between SNPs in DARC and asthma preva-
lence in African descendants81; however, the immunological basis by
which DARC contributes to the pro‐asthmatic phenotype is not fully
delineated. Chapman and colleagues employed DARC knockout
(DARCΔE2) mice to examine the contribution this molecule to the
development of AAD.77 The authors show that house dust mite
(HDM) challenge of WT mice increased DARC expression in alveolar
airway epithelial cells and that HDM challenge of WT and DARCΔE2
mice induced a comparable pulmonary cellular infiltrate and immune
phenotype (Th1 Th2 and Th17 associated cytokines). The only nota-
ble differences between WT and DARCΔE2 mice were increased pul-
monary neutrophils in DARCΔE2 mice suggesting that DARC
contributes to the resolution of neutrophil leak information. Chemo-
kine analyses of the BALF did reveal altered level of DARC‐binding
chemokine CXCL2 in DARCΔE2 mice compared with WT mice. While
the authors did not observe a major impact of ablation of DARC on
the exacerbation of the allergic airway inflammatory phenotype,
DARC did appear to regulate the severity and resolution of HDM‐
induced airway hyper‐responsiveness (AHR). AHR measured by both
tissue resistance and elastance was significantly reduced in the
DARCΔE2 compared to WT mice. Interestingly, ablation of DARC did
not alter HDM‐induced airway remodelling as the level of mucus
hyperplasia and collagen deposition was comparable between HDM‐
challenged WT and DARCΔE2 mice. These observations in animal
systems prompted the investigators to examine for associations
between DARC SNPs and symptoms in healthcare utilization in an
asthma cohort. The authors identified a SNP in DARC (rs12042349)
that was associated with worse asthma control in a poorly controlled
white asthmatic cohort. Collectively, these experimental‐based and
clinical observations suggest that DARC may contribute to altered
severity and resolution of AHR.
The functional role for B cells in allergic asthma phenotype has
been controversial. Previous reports employing B cell deficient mice
have shown the B cells are not required for eosinophilic inflamma-
tion and induction of the asthma phenotype.82-84 However, there is
emerging evidence to suggest that B cells may interact with DC cells
to promote the differentiation of IL‐4 committed follicular T helper
(Tfh) cells into memory CD4+ Th2 cells.85 Vroman and colleagues
employing a chronic HDM provocation mouse asthma model
revealed that the absence of B cells or lack of CD40L signalling (B‐T
cell interaction) does not impact pulmonary eosinophilic inflamma-
tion.86 The authors further demonstrated that loss of B cells or B‐T
cell interaction impacted the frequency of T follicular helper (Tfh)
and CD4+ Th2 cells, however, had no impact on the type II innate
lymphoid cell (ILC2) frequency. Notably, the loss of B cells and B‐T
cell interaction did not impact pulmonary eosinophilic inflammation
but led to reduced pulmonary remodelling as the HDM treated
Mb1−/− and CD40l−/− mice had reduced airway remodelling and
AHR. The pulmonary eosinophilic inflammation in the presence of
reduced CD4+ Th2 immunity is likely to be attributed to normal
ILC2 functionality as ILC2s are a prodigious source of the cytokines
IL‐5 and IL‐13 which orchestrate eosinophil differentiation and matu-
ration recruitment and effector function.87-89 The authors speculate
that divergence between these data sets and previous studies
employing HDM‐driven asthma models with a short challenge phase
may relate to the formation of iBALTs (inducible bronchus‐associated
lymphoid tissue). Short allergen challenge protocols do not promote
the formation of iBALTs, whereas Chronic HDM exposure as used
by Vroman and colleagues promotes the development of iBALTs
which possess IgE‐expressing GC B cells, plasma cells as well as Tfh
Th2 cells. Loss of B‐T cell interaction and iBALT structures in the
lung of chronically HDM exposed Mb1−/− and CD40l−/− mice led
to reduced Tfh and CD4+ Th2 cell numbers in the presence of nor-
mal ILC2s. The authors conclude that B‐T cell interaction is required
for robust Tfh and Th2 cell induction but not essential for eosinophi-
lic airway inflammation during a chronic HDM‐driven asthma model.
4.1.2 | Molecular mechanisms of allergic airway
remodelling
Kondo and colleagues examined the involvement of Tmem16A
[Anoctamin 1 (Ano1)] a Ca2+‐activated chloride (Cl−) channel in gob-
let cell (GC) metaplasia in a guinea‐pig asthma model.90 Previous
studies have reported that Ano1 modulates mucus secretion and air-
way smooth muscle contraction in experimental asthma.91,92 The
authors show that in vitro antigen (ovalbumin [OVA]) challenge of
the trachea from OVA‐sensitized guinea‐pigs and not non‐sensitized
guinea‐pigs induced a rapid chloride (Cl−) ion secretion that was
dependent on TMEM16A activity. Notably the sensitized airway
epithelium demonstrated increased frequency of GCs and that
in vitro OVA‐challenge stimulated GC secretion that was dependent
Tmem16A activity. Immunofluorescence analyses revealed that
TMEM16A was predominantly localized to the apical membrane of
the sensitized epithelium and mucus granules in GC and basal cells.
Employing an in vitro airway epithelial culture system the authors
show that IL‐13 treatment of airway epithelial cells led to MUC5AC‐
positive GC metaplasia that was strongly associated with increased
TMEM16A expression and enhanced Ca2+‐activated TMEM16A‐
dependent Cl− secretion. Collectively these studies suggest that
ANO1 may contribute to GC metaplasia and mucus secretion during
pulmonary allergic inflammation.
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During a pulmonary allergic response aeroallergens are thought to
lead to the release of mast cell‐derived mediators including histamine
and leukotrienes which can act as secretagogues and activate Ca2+
signalling cascades93,94 making it tempting to speculate that mediators
such as histamine and leukotrienes stimulate GC ANO1‐dependent
Cl− activity and promote airway mucus secretion. The molecular basis
of how a Ca2+ signal activates ANO1 activity remains unclear.95
Experimental evidence suggests that Ca2+ directly binds to ANO1 pro-
tein and activates Cl− ion transport. However, there is emerging data
of the interaction of other proteins including calmodulin (CaM) and
annexin A1 that may regulate the Ca2+‐activated Cl− channel activ-
ity.96-98 The authors’ demonstration that the Cl− transport response
was dependent on TMEM16A clearly indicates that respiratory aller-
gen induces a Ca2+‐dependent Cl− ion transport via TMEM16A and
not by cAMP‐dependent Cftr‐mediated Cl− ion transport. Intriguingly,
the authors revealed ANO1 expression in the proliferative basal cells
within the airway epithelium. In recent years, there has been emerging
interest in the role of bioelectric circuits in the regulation of cellular
proliferation.99 These studies have revealed a roles for bioelectric reg-
ulation and activation of Cl− currents by Ca2+‐activated Cl− channels
(ClC3) and chloride intracellular channels (CLIC5) in cellular prolifera-
tion.99 Consistent with this argument, AN01 gene is overexpressed in
oral head and neck squamous cell carcinomas and level of expression
correlates with cell proliferation.100 With respect to the role for Ca2+‐
dependent Cl− ion transport in mucus secretion, it is postulated that
the influx of Cl− ions into the granule GC granule is important in the
disruption of cationic shielding which leads to rapid swelling exocyto-
sis and hydration of the mucus.101,102 Additionally, ANO1‐dependent
Cl− transport activity may also contribute to Cl−/bicarbonate exchange
through SLC26A4 which is also important in supporting mucin
release.103 Given the demonstration that ANO1 may be a key regula-
tor for hypersecretory diseases such as asthma and GC hyperplasia
and mucus secretion, this would make them an attractive candidate
for asthma therapeutics.
4.1.3 | The impact of allergic comorbidities on
allergic phenotypes
Epidemiological reports indicate an association between food sensitiza-
tion and increased risk for the development of allergic diseases, in par-
ticular asthma.104-107 Furthermore, it is well‐established that asthma is
a comorbidity for the development of severe food anaphylactic reac-
tions.108-110 Utsch and colleagues employing an experimental model to
peanut (PN)‐induced food allergy examined the impact of food sensiti-
zation on aeroallergen (HDM) sensitization and the development of
asthmatic phenotype.111 The authors show that prior sensitization to
PN enhanced HDM‐induced Th2 responses in the lung. Surprisingly,
the increased CD4+ Th2 cytokine response was not associated with
enhancement of HDM‐induced asthma manifestations such as pul-
monary eosinophilic inflammation, mucus hypersecretion and AHR.
Given the previous demonstrations that CD4+ Th2 cells and ILC2 cells
are important in the augmentation of the food allergic response, it
would suggest that the pre‐existing peanut food allergic response
provides an unspecific bystander activation for the HDM‐sensitization
leading to increased Type II cytokine production.112 Intriguingly, the
HDM‐induced airway inflammation while enhancing the mast cell
response did not seem to impact the anaphylactic response to PN.
However, the lack of effect of HDM‐sensitization on exacerbation of
the PN‐induced anaphylactic reaction may relate to the induction of
both a IgG1‐basophil/macrophage and IgE‐MC‐dependent responses113
following systemic antigen challenge and potential masking of any dif-
ferences in the IgE‐mediated induced clinical symptoms.
4.1.4 | Inhibiting airway inflammation and
remodelling
A major histopathologic manifestation of asthma is the onset of air-
way remodelling, which is thought to contribute to the irreversible, or
partially reversible, airflow obstruction and ultimately unresponsive-
ness to asthma therapies such as corticosteroids.114-116 Recently,
there has been advancement in the utilization of mesenchymal stem
cells (MSCs) in the treatment of pulmonary disease phenotypes.117
Human mesenchymal stem cells (huMSCs) are non‐hematopoietic
multipotent stromal cells that have regenerative properties and signif-
icant immunosuppressive potential and are well tolerated following
allo‐ and xeno‐transplantation.118-121 Given this potential
immunomodulatory capacity, Kang and colleagues investigated the
immunomodulatory impact of huMSCs on the development of the
asthma phenotype in mice. The authors show that human umbilical
cord blood derived MSCs administered to antigen‐sensitized mice
suppressed the development of antigen‐induced AHR. The reduction
in AHR was importantly associated with a significant reduction in pul-
monary inflammation including Th2 cytokine production, eosinophilic
infiltration and airway remodelling (smooth muscle hypertrophy and
mucus hypersecretion). Notably the protective effects of the huMSCs
were associated with an increase in the frequency of CD4+ CD25+
FoxP3+ TR cells and production of the pro‐inflammatory cytokines
IL‐10 and TGFβ1. The molecular mechanisms by which MSCs induce
T regulatory expansion are not yet fully delineated. Experimental evi-
dence suggests that MSCs can induce TR cells responses via contact‐
dependent mechanisms through inducible T cell co‐stimulator (ICOS)
—ICOSL and potentially through contact‐independent mechanisms
involving indolamine 2,3‐dioxygenase (IDO).122,123 These studies are
the first demonstration of xenogenic huMSC‐mediated suppression
of the allergic asthma phenotype. While further studies are required
to delineate the molecular basis of huMSC‐mediated up regulation of
TR cells and the protective effects against allergen‐induced asthma
phenotype, this shows great promise in the utilization of these cells
for the prevention or treatment of allergic disease.
4.2 | Food allergy and anaphylaxis
4.2.1 | Oral tolerance
As food allergy has become a major public health concern, there has
been increasing interest in the understanding of the immunological
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processes that regulate oral tolerance versus sensitization.124 In non‐
food allergic individuals, food antigens promote immune tolerance
associated with the expansion of FoxP3+ TR cells and also IL‐10 or
IFNγ‐secreting TR1 cells.125 In food allergic individuals, exposure to
innocuous dietary antigens leads to an inappropriate CD4+ Th2
response associated with pro‐Type II cytokine production (IL‐4, IL‐5,
IL‐9, IL‐13) ILC2 response which leads to priming of the basophils and
mast cells and development of food‐specific IgE.124,125 Currently, the
behavioural and environmental determinants that favour oral immune
tolerance vs sensitization to foods are not fully understood. Recent
clinical evidence suggests that early introduction of solid foods in the
diet such as egg and peanut can be beneficial and promote food toler-
ance.126-129 Furthermore, introduction of solid foods while continuing
breastfeeding is also thought to enhance tolerance induction and pre-
vention of food allergy possibly through the presence of immunomod-
ulatory factors such as TGFβ in breastmilk.130 Rekima and colleagues
examined a birth cohort that consisted of mother‐child pairs from the
French EDEN birth study and surprisingly detected egg antigen (OVA)‐
specific IgG and IgA in breastmilk from allergic and not allergic moth-
ers.131 While OVA‐specific IgA levels in mother milk from allergic and
non‐allergic mothers were similar, the level of OVA‐specific IgG was
found to be significantly higher in milk from allergic mothers compared
with non‐allergic mothers. These clinical observations prompted the
question of whether oral antigen exposure through breastmilk could
prevent food allergy in young offspring the investigators employed a
mouse model of food allergy.99
The author shows that mice breastfed from OVA‐sensitized
mothers who were exposed to OVA during lactation had decreased
food allergy susceptibility at 6 weeks of age. Notably the protective
effects were temporary as food allergen exposure to breastfed pups
at 13 weeks of age‐induced food allergy. In efforts to prolong the
breastfeeding‐mediated suppressive effects, the authors administered
a TGFβ‐enriched formula to mice post weaning. The authors show
that post weaning oral supplementation with TGFβ prolonged the
beneficial effects of breastfeeding as breastfed pups at 13 weeks of
age was protected from the development of food allergy. Interest-
ingly, the TGFβ‐enriched formula protective effects were not associ-
ated with enhanced FoxP3+ TR populations but rather improved
gastrointestinal (GI) epithelial barrier function in the mice suggesting
that TGFβ‐enriched formula significantly improved GI barrier func-
tion. Previous experimental studies have demonstrated that TGFβ
stimulation of intestinal epithelial cells enhances epithelial barrier
function via increased expression of tight junction proteins claudin‐1
and claudin‐4 via the SMAD‐signalling axis.132,133
Recently, there has been increasing reports of food allergic reac-
tions to food additives.134,135 In Denmark, it is reported that a
prevalence of 1%‐2% of children and about 1% of adults have had
an adverse reaction to food additives.135 Food additives are defined
as substances added to food at any stage of production, processing,
treatment packaging or storage, and there are currently greater than
3000 substances approved for use as food additives by the US Food
Drug Administration. Yamashita and colleagues evaluated the ability
of artificial sweeteners and mixtures of food additives to break oral
tolerance and induce food allergy in mice.136 The authors assessed a
number of sweeteners (acesulfame potassium, aspartame, xylitol and
meso‐erythritol), moisture absorber (silicon dioxide), natural sugars
(glucose and sucrose) and other additives such as benzoic acid,
sweetener saccharin sodium and annatto pigment. The authors show
that co‐administration of food additives including acesulfame, ery-
thritol, glucose and sucrose and egg antigen (OVA)‐specific IgE, how-
ever, saccharin induced a robust OVA‐specific IgE suggesting that
saccharin could break tolerance and promote sensitization. The
authors further demonstrated that administration of OVA with sac-
charin could prevent the acquisition of oral tolerance and promote
food sensitization and food allergy. The authors show that saccharin‐
induced sensitization was associated with altered migration of classi-
cal antigen‐presenting cell APCs.
Intriguingly, the authors assessed the risk of pleural food additives
in the induction of food sensitization and development of food
allergy.136 The authors show that exposure of mice to a mixture of
pleural food additives that were at a concentration equivalent to the
average daily intake (ADI) of the Food Safety Commission in Japan/
the joint FAO/WHO expert committee on food allergy additives in
the presence of OVA promoted OVA sensitization and food allergy.
Importantly, exposure to single food additives while promoting OVA‐
specific IgE did not predispose to OVA‐induced food allergy. How-
ever, exposure to a mixture of food additives or saccharin not only
promoted OVA‐specific igE but also predisposed to the induction of
food allergy following subsequent exposure to the allergen OVA.
Food additive treatment of saccharin or mixture led to altered migra-
tion of APCs reducing proportions of MHCII+ CD11b+ CD103+
APCs and augmented MHCII+ CD11b+ CD103− APCs. While the
dose of saccharin sodium used per mouse (100 mg) corresponded to
100 times the ADI dosage of additives, the mixture of food additives
was only approximately 10 times the ADI dose and was sufficient to
break immune tolerance and promote food allergy. These results sug-
gest that intake of pleural additives amplifies the risk of developing
food allergies. The breaking of oral tolerance appeared to be associ-
ated with altered balance of tolerogenic CD11b+ CX3CR1+ CD103+
DCs and allergic resident CD11b+ CD103− DCs which is consistent
with previous investigations demonstrating that CD11c+ positive
CX3CR1+ DCs drive immune tolerance where is the CD11b+ DCs
are associated with the induction of allergic responses.137
Lozano‐Ojalvo and colleagues utilized a different approach and
examined whether a hydrolysate of the egg antigen (OVA) could pre-
vent and/or possibly treat egg allergy.138 The investigators demon-
strated that the hydrolysate of ovalbumin (OVA‐H) lacked sensitizing
eliciting potential in an in vivo mouse model. Moreover, administration
of the OVA‐H and not egg white (EW) in the presence of cholera toxin
(CT) did not induce OVA‐specific IgE and IgG1. Consistent with this
observation, subsequent exposure to OVA‐H did not promote the
development of CD4+ Th2 response and development of anaphylactic
symptoms in the mice. These studies suggest that OVA‐H was weakly
immunogenic and hypoallergenic. The authors next assessed the pro-
phylactic potential of OVA hydrolysate in the development of allergy
to EW in mice. The authors show that pre‐treatment of mice with
ROBERTS ET AL. | 1613
OVA‐H prior to EW plus CT prevented sensitization and the develop-
ment of anaphylaxis following oral challenge with EW. The pre‐treat-
ment of mice with OVA‐H was associated with an increased FoxP3+
TR phenotype expression of regulatory cytokines IL‐10 and TGFβ.
These results indicate that pre‐treatment with a hydrolysed form of
antigen (OVA‐H) can more effective in the inhibition of EW allergy in
mice than the intact antigen (OVA). Notably, the OVA‐H induced sus-
tained desensitization to EW in mice suggesting that OVA‐H may pro-
vide effective immunotherapy with durable effects.
Antidotal clinical data suggest that the gastric pathobiont Heli-
cobacter pylori (H. pylori) may confer protection against oesophageal
disorders as well as asthma, allergy and IBD.139 Further support of
this concept is large epidemiological studies revealing an inverse
association with H. pylori and development of allergic diseases such
as allergic asthma.140 Kyburz and colleagues investigated whether
experimental infection with H. pylori or prophylactic treatment with
the H. pylori‐derived immunomodulatory vacuolating cytotoxin A
(VacA) molecule can impact the onset and severity of food allergy
and anaphylaxis.141 The investigators show that infection of neonatal
mice with H. pylori or treatment of animals with H. pylori VacA
reduced the rate of allergen sensitization and subsequent develop-
ment of anaphylaxis following allergen challenge. The authors
showed that the protective effect in mice was associated with a
stable TR response associated with demethylation of the TR‐specific
demethylated region (TSDR) within the FoxP3 locus. These studies
suggest that H. pylori possesses strong immunomodulatory proper-
ties mediated at least in part by the VacA protein that leads to
enhanced T regulatory response and protection from food allergy.
Clinical study performed in rural alpine area of Switzerland has
revealed that children raised on farms have less allergies than children
living in the same area but not on a farm.142 This was supported by a
cross‐sectional study including farmers and non‐farmers children from
Austria, Germany and Switzerland that revealed the protective farming
effect where the presence of cattle and other animals provided a
strongly protective environment against atopy in young children.143 A
limitation to our understanding of the molecular mechanisms involved
in the driving the protective farming effect is the lack of appropriate
animal model systems. To begin to address, Frossard and colleagues
developed a mouse model system that mimics the farm versus non‐
farm (University animal facility) environments to assess the influence
of microbial environment on allergy susceptibility.144 The authors
stratified Balb/c mouse breeding colonies into two different environ-
ments (a) cattle barn of a typical Alpine farm in rural western Switzer-
land, where the mice are located in the same area as the cows and
naturally exposed to cows and hay dust and (b) controlled environ-
ment where mice are bred in a conventional animal facility at the
University of Geneva school of medicine under SPF conditions (AF).
The investigators took the F2 generation mice and showed that mice
from both locations were in good health and demonstrated compara-
ble weight gain. Examination of the susceptibility to allergen‐induced
contact hypersensitivity revealed that the farm environment protected
mice from skin allergy. The farm mice had reduced levels of antigen‐
specific IgE and IgG3 compared to the AF mice. Analysis of the
peripheral blood revealed that the farm mice displayed less B (CD19+)
cells and heightened level of CD3+ CD4+ T cells suggesting CD4+ T
cell activation by the farm environment. Analyses of gut microbiome
revealed significant microbiome differences between farm and AF
mice. Interestingly, the proportion of several bacterial genera (Lacto-
bacillus, Alistipes, Roseburia, Adlercreutzia and Clostridium) which are
known to have immunomodulatory properties was significantly differ-
ent between farm and AF mice making it tempting to speculate that
the commensal microbiota may potentially regulate the innate and
adaptive immune compartment and alter susceptibility to allergic con-
ditions. While the contribution of the altered peripheral blood T cell
phenotype and cytokine production or microbiota to the allergen‐
induced contact hypersensitivity responses was not ascertained, this
study sets an excellent platform to begin to distinguish the molecular
pathways that may contribute to the environmental factor modulation
of allergy susceptibility outcomes.
A study by Malik and colleagues performed genomic and
immunohistochemistry analysis on positive house dust mite (HDM)
atopy patch test (APT) from patients with and without AD and
healthy controls.145 The investigators performed HDM patch test on
normal appearing back of 30 individuals of which 15/30 responded
positively to HDM. Of the 15 individuals who responded positively
four had coexisting AD and four others had elevated IgE. The positive
HDM lesions contained higher T cell, eosinophil and DC cell infil-
trates versus controls. Microarray analysis revealed that HDM‐posi-
tive skin reactions versus control skin induced an increase of 743 and
decrease of 326 differentially expressed genes. The upregulated
genes included inflammation/immune activation phenotype (Th2 and
Th17, Th22/Th17 and Th9), and down regulated genes included
selective barrier and lipid genes. Notably, the terminal differentiation,
tight junction and lipid genes characteristically down regulated and
AD were not decreased in HDM. Analyses revealed that HDM
responses in individuals with concomitant AD displayed a more
robust inflammatory response to HDM than non‐AD individuals.
Pathway enrichment analysis of the HDM transcriptome revealed
many significant upregulated pathways in the HDM signature includ-
ing T cell receptor, NOD, Toll‐like receptor signalling, JAK‐STAT sig-
nalling, interferon gamma signalling and Th22. This was the first
comprehensive molecular profiling of positive HDM APT responses
of human skin. While the HDM APT demonstrated a strong Th2
response, HDM lesions illustrated some qualitative differences in Th2
induction and epidermal abnormalities as compared to AD.
Another entity of food hypersensitivities is eosinophilic gastroin-
testinal disorders (EGIDs). Eosinophilic esophagitis (EoE) is the most
common form of EGIDSs in humans with symptoms related to eosi-
nophil predominate mucosal inflammation and oesophageal dysfunc-
tion.146,147 Patients with EoE have a high rate of concurrent IgE‐
mediated food allergy and food elimination diet, and amino acid
feeding is one of the mainstay therapies for young children with
EoE.148,149 Recent clinical studies have revealed efficacy of epicuta-
neous immunotherapy (EPIT) in peanut allergic children.150 To exam-
ine the potential impact of EPIT on EGIDs, Mondoulet and
colleagues developed a model of gastric eosinophilia in peanut‐
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sensitized piglets.151 The authors show that intraperitoneal sensitiza-
tion to peanut protein extract (PPE) and subsequent oral exposure
led to a gastric eosinophilia. Treatment of piglets with active EPIT by
using the VIASKIN loaded with PPE applied daily to the ear induced
a significant reduction in median antigen‐specific IgE, number of gas-
tric mucosal lesions and histological improvement including reduced
gastric mucosal eosinophil numbers. The reduction in the gastric
eosinophil phenotype was associated with reduced GATA‐3, IL‐5 and
CCL11m RNA expression in splenocytes. These studies suggest EPIT
may be an efficacious approach to treat peanut‐induced EGIDs.
Metal allergies are generally classified as a Th1‐dependent hyper-
sensitivity response. Nickel (Ni) is the most frequent metal allergen
among various metals, and the mechanism by which small metal anti-
gens induce specific immune responses is currently unclear. Sato and
colleagues recently developed a mouse model of Ni allergy utilizing
lipopolysaccharide (LPS) as an adjuvant152 and revealed an interac-
tion between TLR signalling and Ni in the development of nickel
allergy. In their recent study, Kuroishi and colleagues perform a ser-
ies of elegant studies to show that LPS stimulates the production of
the chemokine, CXCL4 which acts as a Ni‐binding protein and exac-
erbates Ni allergy. Performing a series of in vivo mouse experiments
in combination with tandem mass spectrometry and surface plasmon
resonance analyses, the authors show that (a) LPS stimulates CXCL4;
(b) CXCL4 binds Ni and (c) that co‐administration of CXCL4 and Ni
augmented Ni allergy at both the elicitation and sensitization phase.
Flow cytometric analysis suggests that CXCL4 chemotactic activity is
not responsible for the augmenting effects. These studies clearly
identified CXCL4 as a novel Ni‐binding protein and demonstrate a
role for this chemokine in augmentation of nickel allergy. While fur-
ther studies are required to delineate the mechanism by which
CXCL4 augments nickel allergy and or whether interactions between
CXCL4 and other metal antigens such as cobalt or palladium occur
in metal allergies, this information will be useful in the development
of effective methods to prevent and treat metal allergy.
5 | BASIC MECHANISMS IN ALLERGIC
DISEASE
The nature of a cell's energy metabolism is closely tied to its function,
and recent research has started to shed light on how targeting cell
metabolism could be a novel avenue for therapeutic interventions in
respiratory diseases. In particular, reports have shown that in some
chronic inflammatory settings, myeloid cells undergo metabolic repro-
gramming from oxidative phosphorylation of glucose to the oxidation
of fatty acids. Al‐Khami and colleagues investigated the impact of the
fatty acid oxidation pathway on the magnitude of a mouse model of
asthma by pharmacologically blocking it with Etomoxir.153 The result
was a clear reduction in the overall inflammatory response. The lack
of cell specificity inherent to this type of approach clearly has its
caveats, but given there is existing medication which can block fatty
acid oxidation, there is potential for rapidly harnessing this novel
therapeutic approach should further research support its application.
Cell‐to‐cell communication occurs through the release of sol-
uble mediators such as cytokines and chemokines, and then their
recognition by cognate receptors on responding cells. Alternatively,
direct cell‐to‐cell contact via receptor‐ligand pairs is a fundamental
mechanism of cellular communication. Another mechanism, as
investigated by Gon and colleagues, is through extracellular vesi-
cles, which are cell‐derived membranous structures that are shed
from the cell surface.154 These extracellular vesicles can contain
cellular components such as microRNA's, and the nature of their
content differs depending on the activation and differentiation
state of the cells. Gon and colleagues reported that during house
dust mite induced allergic airway inflammation in mice, there is an
8.9‐fold increase in extracellular vesicles that are secreted into the
airways. Importantly, the microRNA constituents of these vesicles
were different between sham‐control and house dust mite exposed
animals, with the vesicles from house dust mite exposed airways
having diminished microRNAs targeting Th2 transcripts such as IL‐
13 and IL‐5R. Overall, these data highlight the likely role of vesi-
cles and their microRNA constituents in regulating the magnitude
of allergic responses in the airways.
The pathological role of mast cells in allergic diseases, often insti-
gated following cross‐linking of IgE on their surface, is well estab-
lished. Clinical desensitization with specific allergens is a common
and effective means to induce tolerance; however, this tolerance is
not long‐lasting and can recur following allergen withdrawal. Lewis
and colleagues used an in vitro culture to assess whether human
mast cells recover from IgE‐mediated desensitization.155 Following
removal of the allergen, the mast cells recovered their effector func-
tion within days, suggesting this process of sensitization might be
mediated by the temporary accumulation of intracellular inhibitors,
as opposed to a fundamental change in the cellular programme, for
example, by epigenetic modifications.
Are mast cells always bad? Salamon and colleagues provided data
which suggest we might need to rethink the role of mast cells in
allergic dermatitis.156 Using in vitro cultures and a mouse model, the
authors showed that following stimulation with IL‐33 and IgE, mast
cells produced IL‐2 that could promote the expansion of regulatory
T cells. This pathway of pro‐inflammatory signals eventually leading
to a regulatory pathway might represent a key mechanism through
which allergic inflammation is resolved.
6 | CLINICAL MECHANISMS IN ALLERGIC
DISEASE
6.1 | Probiotic supplementation
Several reports in 2017 focused on immune changes in children and
adults following various interventions. Ro and colleagues examined
the effects of maternal probiotic supplementation on discrete T
helper (Th) subsets in relation to the development of AD in offspring
during the first 2 years of life.157 Analysis of 5 discrete Th subsets in
the peripheral blood revealed that those children in the probiotic
group had a reduced proportion of Th22 cells, vs the placebo group
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at age 3 months, regardless of whether AD was present at aged 2.
Moreover, increased Th22 cells were evident in those children who
developed AD. Statistical modelling indicated a partial role for the
reduction of Th22 cells by probiotics in preventing AD. Th22 cells,
which secrete IL‐22, IL‐13 and TNF‐alpha, act directly on ker-
atinocytes via IL‐22. As such, they are candidates for promoting
inflammatory processes in the skin that lead to AD, despite their low
numbers relative to other Th types.
6.2 | Immunotherapy
In other work, circulating invariant natural killer T cells (iNKTs) were
assessed in the blood of children who received oral immunotherapy
(OIT) for cow milk allergy (CMA).158 These cells, which respond to
lipid antigens, had previously been shown by the investigators to be
lower in CMA. In the present study, increased numbers of iNKTs
were associated with OIT, along with a switch in cytokine profile
from Th2 to Th1. Notably, children were able to reintroduce milk in
their diet after OIT and increased iNKTs persisted for several months
after completion of the OIT regimen. These results warrant further
examination of iNKTs in allergen desensitization to foods.
Sensitization to multiple foods is common in patients with food
allergy. With this in mind, Gomez and colleagues tested whether
sublingual immunotherapy targeting a peach protein (Pru p 3) altered
the response to a peanut protein (Ara h 9) belonging to the same
family of highly stable non‐specific lipid transfer proteins.159 Such
“pan‐allergens,” which can induce severe reactions, are widely dis-
tributed across plant food species. Among peach allergic adults,
1 year of Pru p 3 sublingual immunotherapy resulted in decreased
weal size by skin prick test, along with increased threshold upon
food challenge, for both peach and peanut. Similarly, a rise in specific
IgG4 and in the IgG4/IgE ratio was observed for both allergens.
6.3 | Asthma mechanisms
Several papers in 2017 focused on cellular and biologic mechanisms of
asthma. Neutrophils have been widely implicated in the pathogenesis
of severe asthma. While their anti‐microbial function is generally well
understood, their role in asthma pathogenesis remains enigmatic. In
addition to their phagocytic and cytokine‐secreting abilities, neu-
trophils emanate DNA structures that arise from decondensation and
spreading of chromatin in response to a variety of activating triggers.
While such DNA traps (NETs) can capture microbes, work by Pham
and colleagues in the journal points to a pro‐inflammatory role in
asthma.160 Peripheral blood neutrophils from patients with severe
asthma that were stimulated with IL‐8 displayed enhanced autophagy
and NET levels compared with cells from patients with less severe dis-
ease. Notably, higher NET levels were linked to worse lung function,
and the ability to mediate epithelial damage and mediator release from
eosinophils in functional assays, thereby supporting a pathogenic role.
Two papers focused on metabolites in exhaled breath as markers
of disease processes in the asthmatic airways. Kowal et al reported
increased levels of a variety of arachidonic acid metabolites in
patients experiencing bronchoconstriction after bronchial challenge
with dust mite extract.161 These included the potent eosinophil
chemoattractant 5‐oxo‐eicosatetraenoic acid (5‐oxo‐ETE), which is a
product of the 5‐lipoxygenase pathway that also results in leuko-
triene synthesis. Levels of 5‐oxo‐ETE were markedly higher than
other 5‐lipoxygenase metabolites, including leukotriene D4, suggest-
ing an important role in asthma pathogenesis. The second paper con-
ducted a systematic review of 27 studies to assess the diagnostic
accuracy of the fraction of NO in exhaled breath.162 This test, which
can be performed using a hand‐held monitor, may provide an indica-
tor of eosinophilic inflammation of the airways. Diagnostic accuracy
was found to be highly variable, and the results imply that more
work is needed using well‐designed studies to determine the suitabil-
ity of this test within the asthma diagnosis pathway.
6.4 | Rhinitis allergic mechanisms
Other work pointed to an adverse effect of seasonal allergic rhinitis
on cognitive functions related to memory and multitasking.163 This
study highlighted the knowledge gap regarding the actions of various
inflammatory mediators of allergic disease on the central nervous
system.
6.5 | Systemic mastocytosis
Gulen et al addressed whether elevated levels of mast cell mediators
in systemic mastocytosis derive from increased numbers of tissue
mast cells or their increased activation status at the single‐cell
level.164 Assessment of the responsiveness of skin and airway mast
cells both in vitro and in vivo was found to be similar in the face of
increased numbers in blood and urine. The authors proposed that
leakage of mediators from cells explains the high levels of mast cell
mediators in systemic mastocytosis, but acknowledged that more
work is needed to understand the episodic symptoms in this disease.
7 | ALLERGENS
7.1 | House dust mite
In Clinical and Experimental Allergy in 2017, Oseroff and colleagues
have analysed the house dust mite (HDM)‐derived protein targets of
T cell responses in individuals with HDM allergy.165 They used a
mass spectrometry proteomic approach finding 29 known allergens
and 61 novel proteins. T cell reactivity was seen to a large number of
T cell epitopes—15 antigens dominated the response with most
being novel. Most of the known allergens were also IgE reactive but
few of the novel ones were IgE reactive. This will provide lots of new
targets for diagnostics and immunotherapeutics for HDM allergy.
7.2 | Pollens
The current European Union regulatory framework controlling aller-
gen products distinguishes between relevant and non‐relevant
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allergens. Minor allergens are usually not controlled by these regula-
tions. Zimmer and colleagues have looked at three minor birch pollen
allergens (Bet v 4, Bet v 6, Bet v 7) in 70 different products using an
ELIZA system.166 They found large differences within and between
products in minor allergen content with no relationship with major
allergen content. Does this variability impact on characteristics as
diagnostic tools or therapies?
Smiljanic and colleagues have looked at the allergome of the rag-
weed subpollen particles which can be inspired into the lower air-
way.167 These are generated when ragweed is hydrated or exposed
to a thunder storm. The subpollen particles contained large amounts
of the minor Amb a 4 and major Amb a 1 allergens. This suggests
that this is important in ragweed allergy.
Specific IgG4 levels increase with allergen immunotherapy,
and this is thought to be one of mechanisms by which it minimizes
clinical allergy. Groh and colleagues described how they assessed
whether birch pollen immunotherapy generates Bet v 1a IgG4 that
compete with IgE for identical epitopes or whether it has novel epi-
topes.168 They concluded that patients receiving allergen
immunotherapy develop Bet v 1a‐specific IgG4 which competes with
IgE for partly identical or largely overlapping epitopes.
7.3 | Cockroach
In 2017 Clinical and Experimental Allergy, Mindaye and colleagues
described how liquid chromatography and multiple reaction
monitoring mass spectrometry can be used to quantify five German
cockroach allergens (Bla g 1, Bla g 2,Bla g 3, Bla g 4 and Bla g 5).169
Meanwhile, Polley and colleagues described how they looked for
trypsin‐like proteinases in German cockroach allergen extracts.170
Proteinases contribute to allergenicity and airway inflammation by
activating proteinase‐activated receptors. They used a trypsin‐speci-
fic activity‐based probe to detected proteins that were then isolated
using ion‐exchange chromatography. Three serine proteinases were
isolated which showed some homology to Per a 10. The authors
speculate that they may be important in allergen sensitization and
may represent therapeutic targets.
7.4 | Jack Jumper ant venom
Allergy to Jack Jumper ant venom is important in some areas, such as
Australia. Wanandy and colleagues described how they assessed the
consistency of allergenic material and the impact of environmental
factors.171 They found good batch to batch consistency but degrada-
tion above 40°C. This is important to maintain the diagnostic utility
of skin prick testing reagents and efficacy of immunotherapy product.
7.5 | Precautionary allergen labelling
Zurzolo and colleagues have looked at how widely the Australian
food industry is using the VITAL approach to making rational deci-
sions on precautionary allergen labelling.172 A total of 59 manufac-
turers completed the questionnaire. They reported that a quarter of
products had been through the VITAL risk assessment process but
had no PAL statement on the label. They suggested that it might be
helpful if such foods had a permissive “safe to eat” label.
8 | CONCLUSIONS
The year 2017 has provided further advances in the field of allergy.
We look forward to publish more interesting observations in 2019.
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